173186-93-1Relevant articles and documents
Novel (bisarylmethoxy)butylpiperidine analogues as neurotransmitter transporter inhibitors with activity at dopamine receptor sites
Choi, Sung-Woon,Elmaleh, David R.,Hanson, Robert N.,Shoup, Timothy M.,Fischman, Alan J.
, p. 4091 - 4102 (2002)
A series of (bisarylmethoxy)butylpiperidine derivatives was prepared and evaluated in vitro and in vivo to determine the structural requirements necessary for dual activity at the DAT and DA/5-HT receptor sites. These hybrid ligands, constructed by combining pharmacophores specific for the DAT and DA/5-HT receptors, could be useful drugs for treating cocaine addiction by assisting cocaine addicts in maintaining abstinence. The series was evaluated in vitro for DAT and DA/5-HT receptor activity and then selected compounds were tested in vivo for their effects on cocaine-induced hyperlocomotor activity (LMA). The majority of the new compounds demonstrated high to moderate affinity (4-191 nM) for the DAT with 4-hydroxy-4-phenylpiperidine analogues 14 and 15 possessing the greatest affinity. Compounds 15 and 22 exhibited the highest ratio of reuptake inhibition-to-binding (discrimination ratio, DR), 111 and 323, respectively. These derivatives had modest affinity and antagonistic activity for dopamine D2/D3 receptors. Compounds 9 and 15 (DR=0.9 and 111, respectively) stimulated locomotor activity, whereas the other compounds suppressed this response. All compounds tested except for 17 and 21 attenuated cocaine-induced hyperlocomotion.
DIAGNOSTIC AND THERAPEUTIC ALKYL PIPERIDINE/PIPERAZINE COMPOUNDS AND PROCESS
-
Page 29, (2008/06/13)
Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compounds are characterized by the formulae: (I), (II), (III), (IV), (V) wherein: n is an integer of 1 to 6; X, Y, Z1 and Z2 can be the same or different and are hydrogen, halo, haloalkyl, alkyl, aryl, (C1-C6)alkoxy, N-alkyl, (C2-C6)acyloxy, N-alkylene, -SH, -SR, wherein R is from the same group as R1 and R2 and can be the same or different than R1 and R2, amino, nitro, cyano, hydroxy, C(=O)OR6, -C(=O)NR5R4, NR3R2, or S(=O)kR1 wherein k is 1 0r 2, and R1 to R6 are independently hydrogen or (C1-C6)alkyl; R1 and R2 can be the same or different and are hydrogen, (C1-C6)alkyl, hydroxyalkyl or mercaptoalkyl, -C(=O)OR1, cyano, (C1-C6)alkenyl, (C2-C6) alkynyl, or 1, 2, 4-oxadiazol-5-yl optionally substituted at the 3-position by Z4 wherein any (C1-C6)alky, (C1-C6)alkanoyl, (C2-C6)alkenyl or (C2-C6)alkynyl can optionally be substituted by 1, 2 or 3 Z; R7 can be hydrogen, O or phenyl; R8 can be hydrogen, phenyl, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl; Z4 is (C1-C6)alkyl or phenyl, optionally substituted by 1, 2 or 3 Z1; W is O or S; T is amino or C1-C6aminoalkyl; A is N or C; T is C1-C6alkyl or sulfonyl and V is alkyl (C0-C6), alkenyl, alkynyl, haloaryl, alkyl phenol, alkyl halophenyl, and R1 or R2 as indicated above and D is phenyl, naphrhyl, thienyl or pyridinyl.
New N-(benzhydryloxyalkyl)-4-(carboxy/carbamoylmethyl) piperidine derivatives with antidepressant activity
Ahmad, Y. El,Maillet,Laurent,Talab,Teste,Cedat,Fiez-Vandal,Dokhan,Ollivier
, p. 205 - 218 (2007/10/03)
Several benzhydryloxylalkylpiperidine derivatives were prepared with the aim of obtaining new antidepressant compounds. The influence of the length of the aliphatic chain and of aromatic and piperidine ring substitutions was studied. The pharmacological a
